Results for olanzap translation from Latvian to English

niešu izcelsmes indiv diem olanzap na
in a study of caucasians, japanese, and chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.

ieteicam olanzap na s kuma deva ir 10 mg dien.
the recommended starting dose for olanzapine is 10 mg/ day.

katr mut disper jamaj tablet ir 10 mg olanzap na.
each orodispersible tablet contains 10 mg olanzapine

katra mut disper jam tablete satur 5 mg olanzap na.
each orodispersible tablet contains 5 mg olanzapine.

p rtraucot olanzap na lietošanu, deva j samazina pak peniski.
gradual tapering of the dose should be considered when discontinuing olanzapine.

olanzap na iedarb ba šajos p t jumos netika noteikta.
the efficacy of olanzapine was not established in these trials.

pacient m olanzap na lietošanas laik j iesaka p rtraukt z d šanu.
mean infant exposure (mg/ kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/ kg) patients should be advised not to breast-feed an infant if they are taking olanzapine.

olanzap ns tiek metaboliz ts akn s konjug cijas un oksid cijas veid.
olanzapine is metabolized in the liver by conjugative and oxidative pathways.

olanzap nam nav nov rota mijiedarb ba, lietojot kop ar litiju vai biperid nu.
olanzapine showed no interaction when co-administered with lithium or biperiden.

katra mut disper jam tablete satur 10 mg olanzap na (olanzapine).
each orodispersible tablet contains 10 mg olanzapine.

olanzap nu dr kst lietot neatkar gi no dienreiz m, jo uzturs neietekm uzs kšanos.
olanzapine can be given without regards for meals as absorption is not affected by food.

olanzap na mut disper jam s tablet s ir n trija metilparahidroksibenzo ts un n trija propilparahidroksibenzo ts.
sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate olanzapine orodispersible tablet contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate.

b rni un pusaudži olanzap ns nav indic ts b rnu un pusaudžu l dz 18 gadu vecumam rst šanai.
children and adolescents olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.

50 lietošana b rniem un pusaudžiem l dz 18 gadu vecumam olanzap ns nav indic ts b rnu un pusaudžu rst šanai.
use in children and adolescents under 18 years of age olanzapine is not indicated for use in the treatment of children and adolescents.

parkinsona slim ba olanzap na lietošana dopam na agonistu izrais tas psihozes rst šanai pacientiem ar parkinsona slim bu nav ieteicama.
parkinson's disease the use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with parkinson's disease is not recommended.

pacientiem, kas olanzap nu sa muši m nijas epizodes rst šanai, turpiniet terapiju recid vu profilaksei t d paš dev.
for patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose.

cyp1a2 inhib cija nov rots, ka fluvoksam ns – specifisks cyp1a2 inhibitors – stipri kav olanzap na metabolismu.
inhibition of cyp1a2 fluvoxamine, a specific cyp1a2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.

vienlaikus lietojot olanzap nu un valpro tu, bieži zi ots par neitrop niju (skat t apakšpunktu 4. 8).
neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).

olanzap ns in vitro neinhib galvenos cyp450 izoenz mus (piem ram, 1a2, 2d6, 2c9, 2c19, 3a4).
1a2, 2d6, 2c9, 2c19, 3a4).

olanzap na saist šan s ar plazmas olbaltumiem bija apm ram 93%, ja koncentr cija bija apm ram 7 – 1000 ng/ ml.
the plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng/ ml.